Celgene
Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials
MPAACT members will share trial data, aiming to standardize measurable residual disease as a surrogate endpoint for overall survival and speed up drug development.
FDA Approves Bristol Myers Squibb, Bluebird Bio's Multiple Myeloma CAR T-Cell Therapy Abecma
The FDA based its approval on the KarMMa trial, in which 72 percent of evaluable multiple myeloma patients responded to the autologous, anti-BCMA therapy.
Targeted Therapies Continue to Yield Encouraging Data in Studies of IDH-Mutated AML, Glioma
Glioma patients experienced tumors shrinkage, and some AML patients had a complete remission that allowed them to proceed to curative treatment.